AD/PD 2026 Satellite Symposia and Sponsors

Migration, Crosslink

📖

AD/PD 2026 Satellite Symposia and Sponsors

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-events-adpd-2026-satellite-symposia

📖 Wiki Page

event819 wordssynced 2026-04-02

Dates: March 17-21, 2026 Location: Copenhagen, Denmark Organizer: Kenes Group

Overview

flowchart TD events_adpd_2026_satellite_sym["AD/PD 2026 Satellite Symposia and Sponsors"] events_adpd_2026_satellite_sym["Dates"] events_adpd_2026_satellite_sym -->|"related to"| events_adpd_2026_satellite_sym style events_adpd_2026_satellite_sym fill:#81c784,stroke:#333,color:#000 events_adpd_2026_satellite_sym["March"] events_adpd_2026_satellite_sym -->|"related to"| events_adpd_2026_satellite_sym style events_adpd_2026_satellite_sym fill:#81c784,stroke:#333,color:#000 events_adpd_2026_satellite_sym["Location"] events_adpd_2026_satellite_sym -->|"related to"| events_adpd_2026_satellite_sym style events_adpd_2026_satellite_sym fill:#81c784,stroke:#333,color:#000 events_adpd_2026_satellite_sym["Copenhagen"] events_adpd_2026_satellite_sym -->|"related to"| events_adpd_2026_satellite_sym style events_adpd_2026_satellite_sym fill:#81c784,stroke:#333,color:#000 style events_adpd_2026_satellite_sym fill:#4fc3f7,stroke:#333,color:#000

Satellite symposia at AD/PD 2026 provided in-depth educational sessions sponsored by pharmaceutical and biotechnology companies, offering detailed updates on specific therapeutic areas, clinical trial designs, and emerging treatment approaches["@adpd2026"].

Platinum Sponsors

Major Pharmaceutical Partners

Eisai Co., Ltd.

...

Dates: March 17-21, 2026 Location: Copenhagen, Denmark Organizer: Kenes Group

Overview

Mermaid diagram (expand to render)

Satellite symposia at AD/PD 2026 provided in-depth educational sessions sponsored by pharmaceutical and biotechnology companies, offering detailed updates on specific therapeutic areas, clinical trial designs, and emerging treatment approaches["@adpd2026"].

Platinum Sponsors

Major Pharmaceutical Partners

Eisai Co., Ltd.

Session Focus: Leqembi (lecanemab) real-world implementation and long-term outcomes
Key Topics:ARIA management protocols, combination therapy approaches, biomarker monitoring
Presentation Highlights: 36-month CLARITY-AD extension data, real-world effectiveness evidence

Eli Lilly and Company

Session Focus: Donanemab development program and TRAILBLAZER-ALZ results
Key Topics: Biomarker correlations with clinical outcomes, patient selection strategies
Presentation Highlights: Population expansion data, safety profile updates

Roche/Genentech

Session Focus: Tau therapeutics and anti-amyloid pipeline
Key Topics: Gantenerumab long-term data, tau PET tracer development
Presentation Highlights: Next-generation antibody engineering, reformulation approaches

Biogen

Session Focus: Neurology portfolio and gene therapy programs
Key Topics: Alzheimer's pipeline, Parkinson's gene therapy approaches
Presentation Highlights: AAV-based delivery platforms, ASO development

Gold Sponsors

Biotechnology Companies

Denali Therapeutics

Session Focus: LRRK2 inhibitor programs for Parkinson's disease
Key Topics: DNL151 clinical results, BIIB122 development, genetic subpopulation analysis
Presentation Highlights: Target engagement biomarkers, Phase 2 dose selection

AbbVie

Session Focus: Parkinson's disease therapeutics and dyskinesia management
Key Topics: ABBV-951 subcutaneous delivery, alpha-synuclein antibodies
Presentation Highlights: Motor complication management, continuous dopaminergic stimulation

UCB Pharma

Session Focus: Alpha-synuclein modulation and CNS pipeline
Key Topics: UCB0599 small molecule development, precision medicine approaches
Presentation Highlights: Mechanism of action, patient stratification strategies

Alector/AbbVie Collaboration

Session Focus: TREM2-targeted immunotherapy
Key Topics: AL002 agonist development, AL003 anti-TREM2 programs
Presentation Highlights: Microglial modulation, neuroinflammation approaches

Silver Sponsors

Diagnostic and Biomarker Companies

C2N Diagnostics

Session Focus: Fluid biomarker platforms
Key Topics: PrecivityAD platform, p-tau217 assays, mass spectrometry approaches
Presentation Highlights: Clinical utility data, regulatory qualification progress

Fujirebio

Session Focus: Lumipulse automated platforms
Key Topics: Alzheimer biomarker panels, Parkinson's fluid markers
Presentation Highlights: Assay standardization, global accessibility

Roche Diagnostics

Session Focus: Neurology biomarker portfolio
Key Topics: Elecsys platform, amyloid and tau assays
Presentation Highlights: Cross-platform validation, clinical implementation

Research Tools and Services

Thermo Fisher Scientific

Session Focus: Biomarker detection technologies
Key Topics: Ultra-sensitive assay platforms, multiplexing approaches

Charles River Laboratories

Session Focus: Preclinical models
Key Topics: Transgenic models, behavioral testing platforms

Covance/Labcorp

Session Focus: Clinical trial services
Key Topics: Central laboratory services, biomarker assay development

Satellite Symposia Sessions

Educational Track Highlights

Morning Satellite Sessions (Daily 7:00-8:00 AM)

Each morning featured industry-sponsored breakfast sessions:

Day 1: Tau pathology: From mechanisms to therapies
Day 2: Alpha-synuclein seed amplification in clinical practice
Day 3: Microglial modulation: New therapeutic frontiers
Day 4: Biomarker-driven clinical trial design
Day 5: Precision medicine in neurodegenerative diseases

Afternoon Satellite Sessions (Daily 5:30-6:30 PM)

Evening symposia covered:

Day 1: Amyloid removal: Lessons from clinical experience
Day 2: LRRK2 inhibitors: Clinical development updates
Day 3: Gene therapy approaches: Current status and future directions
Day 4: Neuroinflammation: Targeting the complement system
Day 5: Combination therapy strategies: Rationale and evidence

Specialized Workshops

Clinical Trial Design Workshop

Adaptive trial designs for neurodegenerative diseases
Biomarker enrichment strategies
Regulatory pathways for disease-modifying therapies

Biomarker Validation Workshop

Fluid biomarker standardization
PET tracer development pathways
Clinical validation methodologies

Patient Engagement Workshop

Clinical trial diversity
Remote monitoring approaches
Patient-reported outcomes integration

Industry-Funded Research Presentations

Investigator-Initiated Studies

Company-sponsored investigators presented:

Real-world evidence from clinical practice
Post-hoc analyses of clinical trial data
Biomarker sub-studies and correlative science

Young Investigator Awards

Industry-funded awards supported:

Travel grants for early-career researchers
Best abstract presentations
Mentorship programs

Booth Categories

Pharmaceutical Exhibitors

Major pharmaceutical companies showcased:

Pipeline posters and presentations
Clinical trial enrollment information
Medical affairs consultations

Biotechnology Exhibitors

Biotech companies displayed:

Research platforms and technologies
Collaboration opportunities
Investor relations materials

Service Providers

Exhibition hall included:

Contract research organizations
Central laboratories
Imaging core facilities
Data management companies

Networking Events

Industry-Hosted Receptions

Evening networking events featured:

Welcome reception (Day 1)
Sponsor showcase (Day 3)
Closing celebration (Day 5)

Partnering Meetings

Structured partnering sessions allowed:

Academic-industry collaboration discussions
Licensing opportunity meetings
Clinical trial site selection

Key Takeaways

Pharmaceutical engagement remains strong — Major pharma continues significant investment in AD/PD

Biomarker integration — Sponsors increasingly incorporating biomarkers in trial designs

Precision medicine focus — Genetic stratification and patient selection emphasized

Combination approaches — Growing interest in multi-target strategies

Real-world evidence — Post-approval data generation priority for sponsors

References

Unknown, AD/PD 2026 Conference Website (2026)

📖 View canonical wiki page →

Related Entities

events-adpd-2026-satellite-symposia

▸Metadataorigin_type: v1_polymorphic_backfill

slug	events-adpd-2026-satellite-symposia
kg_node_id	None
entity_type	event
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a47f94a0d757
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'events-adpd-2026-satellite-symposia'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

296

Outgoing

302

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

AD/PD 2026 Satellite Symposia and Sponsors

Overview

Platinum Sponsors

Major Pharmaceutical Partners

Eisai Co., Ltd.

Overview

Platinum Sponsors

Major Pharmaceutical Partners

Eisai Co., Ltd.

Eli Lilly and Company

Roche/Genentech

Biogen

Gold Sponsors

Biotechnology Companies

Denali Therapeutics

AbbVie

UCB Pharma

Alector/AbbVie Collaboration

Silver Sponsors

Diagnostic and Biomarker Companies

C2N Diagnostics

Fujirebio

Roche Diagnostics

Research Tools and Services

Thermo Fisher Scientific

Charles River Laboratories

Covance/Labcorp

Satellite Symposia Sessions

Educational Track Highlights

Morning Satellite Sessions (Daily 7:00-8:00 AM)

Afternoon Satellite Sessions (Daily 5:30-6:30 PM)

Specialized Workshops

Clinical Trial Design Workshop

Biomarker Validation Workshop

Patient Engagement Workshop

Industry-Funded Research Presentations

Investigator-Initiated Studies

Young Investigator Awards

Sponsor Exhibition Hall

Booth Categories

Pharmaceutical Exhibitors

Biotechnology Exhibitors

Service Providers

Networking Events

Industry-Hosted Receptions

Partnering Meetings

Key Takeaways

See Also

References

💬 Discussion